Design of a new class of broad-spectrum therapeutics targeted to drug-resistant bacteria

References

• Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 145(1):39–53. doi:10.1016/j.cell.2011.02.022.
   PubMed Web of Science ®Google Scholar
• Ambade SS, Gupta VK, Bhole RP, Khedekar PB, Chikhale RV. 2023. A review on five and six-membered heterocyclic compounds targeting the Penicillin-Binding Protein 2 (PBP2A) of Methicillin-Resistant Staphylococcus aureus (MRSA). Molecules. 28(20):7008. doi:10.3390/molecules28207008.
   PubMed Web of Science ®Google Scholar
• Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 48(suppl_1):5–16. doi:10.1093/jac/48.suppl_1.5.
   PubMed Web of Science ®Google Scholar
• Brennan PJ. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis. 83(1–3):91–97. doi:10.1016/S1472-9792(02)00089-6.
   PubMed Web of Science ®Google Scholar
• Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 47(3):381–389. doi:10.1016/0092-8674(86)90595-7.
   PubMed Web of Science ®Google Scholar
• Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, Blair JMA. 2023. Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol. 21(5):280–295. doi:10.1038/s41579-022-00820-y.
   PubMed Web of Science ®Google Scholar
• Duan F, Xin G, Niu H, Huang W. 2017. Chlorinated emodin as a natural antibacterial agent against drug-resistant bacteria through dual influence on bacterial cell membranes and DNA. Sci Rep. 7(1):12721. doi:10.1038/s41598-017-12905-3.
   PubMedGoogle Scholar
• EClinicalMedicine. 2021. Antimicrobial resistance: a top ten global public health threat. EClinicalMedicine. 41:101221. doi:10.1016/j.eclinm.2021.101221.
   PubMedGoogle Scholar
• EUCAST. 2022. EUCAST reading guide for broth microdilution. V4. https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents.
   Google Scholar
• Firth A, Prathapan P. 2021. Broad-spectrum therapeutics: a new antimicrobial class. Current Research in Pharmacology and Drug Discovery. 2:100011. doi:10.1016/j.crphar.2020.100011.
   PubMedGoogle Scholar
• Fujiwara A, Hoshino T, Westley JW. 1985. Anthracycline antibiotics. Crit Rev Biotechnol. 3(2):133–157. doi:10.3109/07388558509150782.
   Web of Science ®Google Scholar
• Han J-W, Shim D-W, Shin W-Y, Heo K-H, Kwak S-B, Sim E-J, Jeong J-H, Kang T-B, Lee K-H. 2015. Anti-Inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation. Int J Mol Sci. 16(12):8102–8109. doi:10.3390/ijms16048102.
   PubMedGoogle Scholar
• Han M, Vakili MR, Soleymani Abyaneh H, Molavi O, Lai R, Lavasanifar A. 2014. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX Cells. Mol Pharm. 11(8):2640–2649. doi:10.1021/mp500038g.
   PubMed Web of Science ®Google Scholar
• Haque E, Kamil M, Irfan S, Sheikh S, Hasan A, Nazir A, Mir SS. 2018. Blocking mutation independent p53 aggregation by emodin modulates autophagic cell death pathway in lung cancer. Int J Biochem Cell Biol. 96:90–95. doi:10.1016/j.biocel.2018.01.014.
   PubMed Web of Science ®Google Scholar
• Hasan CM, Dutta D, Nguyen ANT. 2022. Revisiting antibiotic resistance: mechanistic foundations to evolutionary outlook. Antibiotics. 11(1):40. doi:10.3390/antibiotics11010040.
   Google Scholar
• Hasanpour AH, Sepidarkish M, Mollalo A, Ardekani A, Almukhtar M, Mechaal A, Hosseini SR, Bayani M, Javanian M, Rostami A. 2023. The global prevalence of methicillin-resistant Staphylococcus aureus colonization in residents of elderly care centers: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 12(1):4. doi:10.1186/s13756-023-01210-6.
   PubMed Web of Science ®Google Scholar
• Jeena MT, Kim S, Jin S, Ryu J-H. 2020. Recent progress in mitochondria-targeted drug and drug-free agents for cancer therapy. Cancers (Basel). 12(1):4. doi:10.3390/cancers12010004.
   Web of Science ®Google Scholar
• Kang S, Sunwoo K, Jung Y, Hur JK, Park K-H, Kim JS, Kim D. 2020. Membrane-targeting Triphenylphosphonium functionalized ciprofloxacin for Methicillin-Resistant Staphylococcus aureus (MRSA). Antibiotics. 9(11):758. doi:10.3390/antibiotics9110758.
   Google Scholar
• Katayama K, Noguchi K, Sugimoto Y. 2014. Regulations of P-Glycoprotein/ABCB1/ MDR1 in human cancer cells. New J Sci. 2014:1–10. doi:10.1155/2014/476974.
   Google Scholar
• Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, Priebe W. 1997. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry. 36(9):2679–2685. doi:10.1021/bi9614489.
   PubMed Web of Science ®Google Scholar
• Lelovic N, Mitachi K, Yang J, Lemieux MR, Ji Y, Kurosu M. 2020. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. J Antibiot. 73(11):780–789. doi:10.1038/s41429-020-0320-7.
   PubMed Web of Science ®Google Scholar
• Lian X, Xia Z, Li X, Karpov P, Jin H, Tetko IV, Xia J, Wu S. 2021. Anti-MRSA drug discovery by ligand-based virtual screening and biological evaluation. Bioorg Chem. 114:105042. doi:10.1016/J.BIOORG.2021.105042.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. 2017. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 7(3):339–348. doi:10.15171/apb.2017.041.
   PubMed Web of Science ®Google Scholar
• Marinello J, Delcuratolo M, Capranico G. 2018. Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci. 19(11):3480. doi:10.3390/ijms19113480.
   PubMed Web of Science ®Google Scholar
• May Zin WW, Buttachon S, Dethoup T, Pereira JA, Gales L, Inácio Â, Costa PM, Lee M, Sekeroglu N, Silva AMS, et al. 2017. Antibacterial and antibiofilm activities of the metabolites isolated from the culture of the mangrove-derived endophytic fungus Eurotium chevalieri KUFA 0006. Phytochemistry. 141:86–97. doi:10.1016/j.phytochem.2017.05.015.
   PubMed Web of Science ®Google Scholar
• Mohan A, Padiadpu J, Baloni P, Chandra N. 2015. Complete genome sequences of a Mycobacterium smegmatis laboratory strain (MC2155) and isoniazid-resistant (4XR1/R2) mutant strains. Genome Announc. 3(1):e01520–14. doi:10.1128/genomeA.01520-14.
   PubMedGoogle Scholar
• Munita JM, Arias CA. 2016. Mechanisms of antibiotic resistance. Vir Mech Bact Patho. 2021:481–511. doi:10.1128/9781555819286.ch17.
   Google Scholar
• Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, … Naghavi M. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 399(10325):629–655. doi:10.1016/S0140-6736(21)02724-0.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. 2011. NIH funds development of new broad-spectrum therapeutics. https://www.nih.gov/news-events/news-releases/nih-funds-development-new-broad-spectrum-therapeutics.
   Google Scholar
• Pathak A, Angst DC, León-Sampedro R, Hall AR. 2023. Antibiotic-degrading resistance changes bacterial community structure via species-specific responses. ISME J. 17(9):1495–1503. doi:10.1038/s41396-023-01465-2.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Kelley SO. 2011. Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells. J Am Chem Soc. 133(10):3260–3263. doi:10.1021/ja110246u.
   PubMed Web of Science ®Google Scholar
• Rabbani A, Finn RM, Ausió J. 2005. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. BioEssays. 27(1):50–56. doi:10.1002/bies.20160.
   PubMed Web of Science ®Google Scholar
• Rai D, Mehra S. 2021. The Mycobacterial Efflux Pump EfpA can induce high drug tolerance to many antituberculosis drugs, including moxifloxacin, in Mycobacterium smegmatis. Antimicrob Agents Chemother. 65(11). doi:10.1128/AAC.00262-21.
   PubMed Web of Science ®Google Scholar
• Riaz MS, Kaur A, Shwayat SN, Behboudi S, Kishore U, Pathan AA. 2020. Dissecting the mechanism of intracellular Mycobacterium smegmatis growth inhibition by platelet activating Factor C-16. Front Microbiol. 11:1046. doi:10.3389/fmicb.2020.01046.
   PubMed Web of Science ®Google Scholar
• Rimal B, Senzani S, Ealand C, Lamichhane G, Kana B, Kim SJ. 2022. Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC–MS. Sci Rep. 12(1):11061. doi:10.1038/s41598-022-15324-1.
   PubMed Web of Science ®Google Scholar
• Sagan L. 1967. On the origin of mitosing cells. J Theor Biol. 14(3):225–274. doi:10.1016/0022-5193(67)90079-3.
   Web of Science ®Google Scholar
• Shia C-S, Hou Y-C, Tsai S-Y, Huieh P-H, Leu Y-L, Chao P-DL. 2010. Differences in pharmacokinetics and ex vivo antioxidant activity following intravenous and oral administrations of emodin to rats**Chi-Sheng Shia and Yu-Chi Hou contributed equally to this work. J Pharm Sci. 99(4):2185–2195. doi:10.1002/jps.21978.
   PubMed Web of Science ®Google Scholar
• Singh SB, Young K, Silver LL. 2017. What is an “ideal” antibiotic? Discovery challenges and path forward. Biochem Pharmacol. 133:63–73. doi:10.1016/j.bcp.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Smith J. 2011. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med. 84:361–369.
   PubMedGoogle Scholar
• Stratton CW. 2003. Dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis. 9(1):10–16. doi:10.3201/eid0901.020172.
   PubMed Web of Science ®Google Scholar
• Sullivan LB, Chandel NS. 2014. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2(1):17. doi:10.1186/2049-3002-2-17.
   PubMedGoogle Scholar
• Van Bambeke F, Mingeot-Leclercq M-P, Struelens MJ, Tulkens PM. 2008. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol Sci. 29(3):124–134. doi:10.1016/j.tips.2007.12.004.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, … Murray CJL. 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Gales AC, Laxminarayan R, Dodd PC. 2023. Antimicrobial resistance: addressing a global threat to humanity. PLoS Med. 20:e1004264. doi:10.1371/journal.pmed.1004264.
   PubMed Web of Science ®Google Scholar
• WHO. 2020. World Health Organization. 10 global health issues to track in 2021.
   Google Scholar
• WHO. 2023a. Global tuberculosis report 2023. https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence = 1.
   Google Scholar
• WHO. 2023b. Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA). https://data.who.int/indicators/i/5DD9606.
   Google Scholar
• Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 55(1):27–55. doi:10.1124/pr.55.1.2.
   PubMed Web of Science ®Google Scholar
• Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B. 2017. Mitochondria-targeted Triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 117(15):10043–10120. doi:10.1021/acs.chemrev.7b00042.
   PubMed Web of Science ®Google Scholar